SCHEMBL20837137

SCHEMBL20837137

COc1ccc(C(N)=O)c2ocnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 2/20 0.40
RPS6KB1 P23443 4/20 0.39
AURKA O14965 3/20 0.39
LMNA P02545 3/20 0.39
KMT2A Q03164 2/20 0.39
MKNK1 Q9BUB5 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
ADORA1 P30542 1/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HSD17B10 Q99714 1/20 0.38
PARP1 P09874 2/20 0.37
MAPK1 P28482 1/20 0.37
MAPK8 P45983 1/20 0.37
MAPK9 P45984 1/20 0.37
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20837398 0.86 LMNA (0.49) LMNAKMT2AKDM4EALDH1A1HSD17B10
SCHEMBL6953728 0.86 TDP1 (0.45) LMNAKMT2AKDM4EALDH1A1HSD17B10
SCHEMBL20837272 0.76 NQO2 (0.40) LMNAKMT2AKDM4EALDH1A1HSD17B10
SCHEMBL20837283 0.74 NQO2 (0.41) LMNAKMT2AKDM4EALDH1A1HSD17B10
SCHEMBL6953997 0.73 PDE4D (0.63)
SCHEMBL20837263 0.72 ALDH1A1 (0.43) KMT2AKDM4EALDH1A1HSD17B10MAPK1
SCHEMBL20837066 0.72 MCL1 (0.38) LMNAKMT2AKDM4EALDH1A1HSD17B10
SCHEMBL20837299 0.72 NQO2 (0.37) KDM4EALDH1A1MAPK1GAAHTT
SCHEMBL20837059 0.71 SMN1; SMN2 (0.42) LMNAKMT2AKDM4EALDH1A1HSD17B10
SCHEMBL7366515 0.70 PARP1 (0.45) NNMTRPS6KB1AURKAMKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 US disclosed
WO-2019055750-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF Aduro Biotech, Inc. (US) 2019-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 NNMT 243/4885RPS6KB1 3543/4885AURKA 1594/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 NNMT 243/4885RPS6KB1 3543/4885AURKA 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.